Biotechnology
Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...
2022-12-13 17:39
1877
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...
2022-12-12 21:50
2245
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...
2022-12-12 21:00
1904
Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...
2022-12-12 20:59
1671
HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to buil...
2022-12-12 10:10
1975
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...
2022-12-11 07:15
3693
Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors
SHENZHEN, China, Dec. 8, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held inShenzhen, China on December 9. A number of major projects in the fields of information technology, artificial int...
2022-12-09 11:16
1730
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...
2022-12-09 06:30
2106
ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit
SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...
2022-12-08 23:00
2558
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...
2022-12-08 22:00
1993
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to participate in upcoming 41th Annual J.P. Morgan Healthcare ...
2022-12-08 21:00
1701
CABIO Showcases the Latest Research Results and Innovative Solutions at Food Ingredients Europe 2022
PARIS, Dec. 8, 2022 /PRNewswire/ -- On December 6, 2022, CABIO Biotech (Wuhan) Co., Ltd (CABIO), a leading Chinese biotechnology company, took part in the three-day Food Ingredients Europe 2022 (Fi Europe) held inParis, France. Fi Europe has been recognized as the industry's highest level interna...
2022-12-08 21:00
2007
Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers
* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses * Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refract...
2022-12-08 14:29
1928
Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022
WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- TIANGEN, a high-tech biological enterprise, demonstrated its revolutionary nucleic acid extraction solution at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), fromDec 4 to...
2022-12-06 21:04
1819
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...
2022-12-06 21:01
2325
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030
* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...
2022-12-06 20:00
1549
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...
2022-12-05 20:00
1545
The First IBCC Unveiled in Hainan
SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) inHainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting. A patient-centered facility, the IBCC serves to improve inpatient experiences as well as medical s...
2022-12-05 15:55
1388
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022
Poster session features a preliminary study result of potential seizure monitoring and detection for patients using SK Biopharmaceuticals' wearable device SK Biopharmaceuticals, Seoul National University Bundang Hospital plan to use Zero WiredTM to further pursue clinical research and develop it...
2022-12-05 08:00
1732
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...
2022-12-03 05:10
3621
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
